No hole in budget, says Austria's Health Minister

3 September 2006

Maria Rauch-Kallat, Austria's Health Minister, has denied claims by the country's health funds that they are headed for a deficit in this election year. Mrs Rauch-Kallat's Austrian People's Party (OVP) and its coalition partner the Alliance for the Future of Austria (BZO) face elections on October 1.

An aggregate deficit of 154.0 million euros ($197.0 million) for the first half of this year has been posted by 21 of Austria's health funds. Despite this, Mrs Rauch-Kallat insists that the situation will break even for the whole year, adding that the health fund forecasts often show discrepancies with actual end-of-year returns.

The FOPI, the research-based drug industry association that mostly includes US drugmakers and subsidiaries in Austria among its members, has provided some support for the Austrian Health Minister's position. The FOPI's president, Boudewijn Van Bochove, predicting that drug spending in Austria for the year would rise by an average of 4%, mostly because of increased volume demand rather than price increases. Mr Van Bochove also suggested that reducing value-added tax on drugs, from 20% to 10%, would reduce the drugs bill by 175.0 million euros.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight